SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as investors analyze its J.P. Morgan Healthcare Conference presentation for critical updates on its oral VK2735 program and commercialization plans, reinforced by a recent Chief Commercial Officer hire and the completion of its obesity maintenance study enrollment. The community is sharply divided between bullish expectations for a significant partnership or buyout, driven by the drug's perceived 'best-in-class' potential, and concerns over stock price suppression and management's strategy within the highly competitive metabolic market.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to strategic announcements around its ambitious "Meta Compute" AI infrastructure buildout, which includes securing multi-gigawatt nuclear energy agreements to power future data centers. This aggressive AI push, alongside reported layoffs in the Reality Labs division, is sparking mixed community reactions regarding the scale of investment versus potential returns. Investors are keenly observing these developments as Meta intensifies its position in the global AI race, with many awaiting further clarity on the long-term vision.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions surrounding potential new tariffs on countries trading with Iran and a reported DOJ probe into Fed Chair Powell, sparking debate on market stability and the independence of the central bank. Despite these headlines, a strong bullish sentiment prevails among many, emphasizing buying opportunities during dips and highlighting the market's resilience. The community is actively discussing whether the market can sustain its upward momentum given these geopolitical and regulatory concerns, often with frustration from those anticipating a significant pullback.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending sharply lower following the FDA's request for additional clarification on the clinical benefit of FILSPARI for FSGS, a development that has caused significant market jitters ahead of its PDUFA decision. While many in the community are concerned this signals a potential Complete Response Letter, a notable counter-narrative suggests the sell-off is an overreaction, pointing to the company's strong commercial execution for FILSPARI in IgAN and solid financial standing as reasons to buy the dip.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to a new partnership and pre-production order with a major U.S. defense contractor, fueling anticipation for a substantial contract to supply advanced computing systems for Army combat vehicles. The community is buzzing with discussion about the immense potential in edge AI and defense, viewing OSS as significantly undervalued with a tight float and strong growth prospects in AI infrastructure, especially after a strategic asset sale to sharpen its focus.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to a significant U.S. Department of Energy (DOE) agreement for Project TETRA, fast-tracking the development and operation of its Integral Molten Salt Reactor (IMSR) pilot. This news has reignited community discussions, with many comparing IMSR favorably to peers like OKLO and highlighting its advanced molten salt technology for meeting growing energy demands, particularly from AI data centers. Investors are optimistic about the DOE agreement as a crucial de-risking catalyst for the stock and the broader advanced nuclear sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to anticipation surrounding its upcoming JPM Healthcare Conference presentation and updated investor materials, which highlight strategic directions including a new 12% market share in Japan. Community discussion is heavily focused on the company's substantial short interest, sparking speculation of a potential short squeeze, while also voicing strong calls for management to secure significant partnerships or a buyout to unlock the value of its vaccine technology.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the U.S. recommendation to add Duchenne Muscular Dystrophy to the newborn screening panel significantly broadens the long-term market for its Elevidys gene therapy. While recent preliminary financial updates led to stock volatility, the community is actively discussing perceived undervaluation and the substantial pipeline potential, particularly in light of expanding early patient identification.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending due to significant community excitement surrounding its multi-year AI partnership with Apple, which will integrate Google's Gemini into Siri and Apple's next-generation Foundation Models. This development is widely seen as a major win in the AI race, solidifying Gemini's competitive position and extending its reach across billions of devices. Conversations highlight Google's expanding AI leadership, including new partnerships in agentic commerce and its implications for the company's market valuation.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is a focal point of discussion following a substantial stock price correction, as investors weigh a CFO transition and positive preliminary Q4 user growth against broader concerns. The community is sharply divided, with bulls highlighting the company's strong user engagement, expanding product offerings, and perceived undervaluation, especially after a recent analyst upgrade. Conversely, bears express skepticism over Duolingo's long-term viability in the face of rapidly advancing AI technologies and question management's focus on user growth over immediate profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to...

Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving Average - Should You Sell?

Verastem (NASDAQ:VSTM) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell...

Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.read more...

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

Equity

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 


Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of...

Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM

Squarepoint Ops LLC increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 2,995.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The...

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat Ratings reports. One...

Insider Selling: Verastem (NASDAQ:VSTM) CEO Sells 2,000 Shares of Stock

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average...

Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 2,000 Shares

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 2,000 shares of Verastem stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $10.07...

BVF Inc. IL Raises Stock Position in Verastem, Inc. $VSTM

BVF Inc. IL grew its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 62.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VSTM News

VSTMVerastem Inc